Leflunomide‐induced toxic epidermal necrolysis

Teraki, Yuichi; Hitomi, Kazuo; Sato, Yutaka; Hamamatsu, Yasushi; Izaki, Seiichi

doi:10.1111/j.1365-4632.2006.03003.x

Cited by 20 publications

(10 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cutaneous reactions caused by leflunomide have been reported in other countries (17)(18)(19)(20)(21)(22). But in China, to our knowedge, there has not severe cutanteous reactions reported caused by leflunomide.…”

Section: Introductionmentioning

confidence: 52%

Severe Cutaneous Adverse Drug Reaction to Leflunomide: A Report of Two Cases

Jian

Guo

Ruan

et al. 2008

Cutaneous and Ocular Toxicology

View full text Add to dashboard Cite

The purpose of this study was to report severe cutaneous reactions in two patients related with leflunomide. A 13-year-old girl was treated with leflunomide for systemic lupus erythematosus. Three months later a progressive generalized blistering formation occurred and epidermolysis appeared on her skin. Methylprednisolone pulse therapy and intravenous immunoglobulin were used to control the severe cutaneous reactions. The patient recovered within 18 days. Another case is a 63-year-old woman who was treated with leflunomide for primary Sjögren's syndrome. Four months later widespread prunosus skin rash appeared on her skin. Methylprednisolone pulse therapy was also used to control the severe cutaneous reactions. The patient was recovered 11 days later. Our report suggests that an association between leflunomide intake and severe cutaneous reactions in rheumatic disease patients should be considered.

show abstract

Section: Introductionmentioning

confidence: 52%

Severe Cutaneous Adverse Drug Reaction to Leflunomide: A Report of Two Cases

Jian

Guo

Ruan

et al. 2008

Cutaneous and Ocular Toxicology

View full text Add to dashboard Cite

show abstract

“…Drug-induced subacute cutaneous lupus erythematosus has been noted in patients with rheumatoid arthritis [31][32][33] (Figs 1 and 2), Sj€ ogren syndrome, 34 and ankylosing spondylitis. 35 Erythema multiforme 36 and toxic epidermal necrolysis [37][38][39] have also been reported. Other dermatologic diseases precipitated by leflunomide include a mucocutaneous lichen planuselike eruption, 40 a photodistributed lichenoid drug reaction, 41 Reiter syndrome, 42 leukocytoclastic vasculitis, 43,44 leg ulcers, 45 alopecia areata, 46 and a syringotropic hypersensitivity reaction.…”

Section: Side Effects and Adverse Cutaneous Eventsmentioning

confidence: 95%

Leflunomide in dermatology

Boyd

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…All of them have been discussed and reported during treatment with Teriflunomide as well. Very rare side-effects of Leflunomide include single cases of toxic epidermal necrolysis (TEN) [ 56 , 57 ], two cases of pericarditis [ 58 ], and two cases of progressive multifocal leukoencephalopathy (PML) [ 59 , 60 ] in approximately 2.1 million patient-years of use [ 61 ]. While there is one case of TEN during Teriflunomide treatment, pericarditis and PML have not yet been reported in patients receiving Teriflunomide.…”

Section: From Leflunomide To Teriflunomidementioning

confidence: 99%

From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis

Aly

Hemmer

Korn

2017

View full text Add to dashboard Cite

Background: Immunosuppressive drugs have been used in the treatment of multiple sclerosis (MS) for a long time. Today, orally available second generation immunosuppressive agents have been approved or are filed for licensing as MS therapeutics. Due to semi-selective targeting of cellular processes, these second-generation immunosuppressive compounds might rather be immunomodulatory. For example, Teriflunomide inhibits the de novo pyrimidine synthesis and thus only targets rapidly proliferating cells, including lymphocytes. It is used as first line disease modifying therapy (DMT) in relapsing-remitting MS (RRMS).Methods: Review of online content related to oral immunosuppressants in MS with an emphasis on Teriflunomide.Results: Teriflunomide and Cladribine are second-generation immunosuppressants that are efficient in the treatment of MS patients. For Teriflunomide, a daily dose of 14 mg reduces the annualized relapse rate (ARR) by more than 30% and disability progression by 30% compared to placebo. Cladribine reduces the ARR by about 50% compared to placebo but has not yet been licensed due to unresolved safety concerns. We also discuss the significance of older immunosuppressive compounds including Azathioprine, Mycophenolate mofetile, and Cyclophosphamide in current MS therapy.Conclusion: Teriflunomide has shown a favorable safety and efficacy profile in RRMS and is a therapeutic option for a distinct group of adult patients with RRMS.

show abstract

Leflunomide‐induced toxic epidermal necrolysis

Cited by 20 publications

References 7 publications

Severe Cutaneous Adverse Drug Reaction to Leflunomide: A Report of Two Cases

Severe Cutaneous Adverse Drug Reaction to Leflunomide: A Report of Two Cases

Leflunomide in dermatology

From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis

Contact Info

Product

Resources

About